SUPPORTING INFORMATION

A tandem mass spectrometry sequence database search method for identification of O-fucosylated proteins by mass spectrometry.

Kristian E. Swearingen^{1*}, Jimmy K. Eng², David Shteynberg¹, Vladimir Vigdorovich³, Timothy A. Springer⁴, Luis Mendoza¹, Noah D. Sather³, Eric W. Deutsch¹, Stefan H. I. Kappe³, Robert L. Moritz^{1*}

¹ Institute for Systems Biology, Seattle, WA, USA

² Proteomics Resource, University of Washington, Seattle, WA, USA

³ Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, USA

⁴Harvard Medical School and Children's Hospital, Boston, MA, USA

*To whom correspondence should be addressed.

kristian.swearingen@systemsbiology.org

robert.moritz@systemsbiology.org

TABLE OF CONTENTS

Fig S1. MSⁿ confirming the identity of fragment spectra arising from neutral loss of O-linked glycans

Fig S2. Neutral loss of O-linked and C-linked glycans at increasing collision energies.

Fig S3. Glycoforms identified by automated sequence database search of data from LC-MS/MS analysis of recombinant *P. falciparum* TRAP

Fig S4. Indistinguishable isobaric glycopeptides from recombinant *P. falciparum* TRAP.

Fig S5. Misidentification of a glycoform in LC-MS/MS of recombinant *P. falciparum* TRAP.

Fig S6. Representative XIC of glycosylated CSP from *P. falciparum* salivary gland sporozoites.

Fig S7. Representative XIC of glycosylated TRAP from *P. falciparum* salivary gland sporozoites.

Fig S8. Representative XIC of glycosylated CSP from *P. vivax* VK210 salivary gland sporozoites.

Fig S9. Representative XIC of glycosylated TRAP from *P. vivax* VK210 salivary gland sporozoites.

Fig S10. Representative XIC of glycosylated CSP from P. vivax VK247 salivary gland sporozoites.

Fig S11. Representative XIC of glycosylated TRAP from *P. vivax* VK247 salivary gland sporozoites.


Fig S12. Representative XIC of glycosylated CSP from *P. yoelii* salivary gland sporozoites.

Fig S13. Representative XIC of glycosylated TRAP from P. yoelii salivary gland sporozoites.

Fig S14. Automated identification of TSR glycosylation in *P. yoelii* salivary gland sporozoites.

Fig S15. Example false positive peptides showing neutral loss of O-linked glycans.

Figure S1. MSⁿ confirming the identity of fragment spectra arising from neutral loss of O-linked glycans. A tryptic digest of recombinant *P. falciparum* circumsporozoite protein (CSP) TSR domain was infused into an LTQ-Orbitrap Elite by nanospray. Precursor ions for the unmodified or O-glucosylfucosylated peptide were isolated and fragmented. All spectra are collision-induced dissociation (CID) collected at high resolution in the Orbitrap. CE = normalized collision energy. Annotated fragment spectra were visualized using a development version of Lorikeet as implemented in the Trans-Proteomic Pipeline.



S1a. CID of the unmodified peptide, $[M+2H]^{++} = 1297 \text{ m/z}$, CE = 35 %. Note that the dominant peaks are y_{13} and y_{14} , the y-ion peaks containing the Pro residue. The y_{13} and y_{14} peaks are the only species visible in the spectra in Figure 1 still bearing the O-linked disaccharide.




Figure S1b. CID of the peptide modified with O-Fuc-Glc, $[M+2H]^{++} = 1451.17 \text{ } m/z$, CE = 23 %. At this CE, some of the precursor is still intact ($[M+2H]^{++}$, red triangle = O-Fuc, blue circle = β 1,3-Glc). Neutral loss of Glc can be seen as a peak at 1370.14 m/z ($[M+2H-Glc]^{++}$, red triangle = O-Fuc). The dominant peak at 1297.11 m/z is the precursor with neutral loss of the O-Fuc-Glc disaccharide ($[M+2H-Fuc-Glc]^{++}$). Peptide fragments are present at low abundance, identifying the sequence of the unmodified peptide.




Figure S1c. MS^3 (CE = 35 %) of the 1370.14 *m/z* fragment seen in Figure S1b produces a dominant peak at 1297.11 *m/z* matching the mass of the unmodified peptide. Many unmodified peptide fragment peaks confirm the sequence of the peptide. This spectrum confirms that the 1370.14 *m/z* peak seen in Figure S1b arises from neutral loss of Glc from the O-Fuc-Glc dissacharide.




Figure S1d. MS^4 of the 1298.11 *m/z* peak seen in Figure S1c ($MS^2 CE = 23 \%$, $MS^3 CE = 25 \%$, $MS^4 CE = 35 \%$). This peak arises from neutral loss of O-Fuc after neutral loss of Glc from the O-Fuc-Glc disaccharide. Fragment ions confirm the sequence of peptide. This spectrum further confirms that the 1370.14 *m/z* peak seen in Figure S1b arises from neutral loss of Glc from the O-Fuc-Glc disaccharide.

Figure S2. Neutral loss of O-linked and C-linked glycans at increasing collision energies.

A tryptic digest of recombinant *P. falciparum* thrombospondin related anonymous protein (TRAP) was analyzed by LC-MS/MS with an LTQ-Orbitrap Elite. Precursor ions for the TSR peptide modified with C-Man and O-Fuc-Glc were isolated and fragmented at sequentially increasing normalized collision energies (CE). All spectra are collision-induced dissociation (CID) collected at high resolution in the Orbitrap. Annotated fragment spectra were visualized using a development version of Lorikeet as implemented in the Trans-Proteomic Pipeline.




Figure S2a. CID at 1329.03 *m*/z, CE = 20 %. The precursor peak is largely unreacted ($[M+2H]^{++}$, green circle = C-Man, red triangle = O-Fuc, blue circle = β 1,3-Glc), though a small peak (~0.3% relative abundance) matches the mass of the peptide after neutral loss of the O-linked disaccharide (1174.98 *m*/*z*, yellow, automatically annotated by Lorikeet as the precursor peak M++).




Figure S2b. CID at 1329.03 *m*/z, CE = 25 %. The dominant peak is still unreacted precursor ($[M+2H]^{++}$, green circle = C-Man, red triangle = O-Fuc, blue circle = β 1,3-Glc). A smaller peak at 1248.01 *m*/z matches the mass of the precursor after neutral loss of Glc from the O-Fuc-Glc disaccharide ($[M+2H-Glc]^{++}$). A third peak at 1174.98 *m*/z (yellow, automatically annotated by Lorikeet as the precursor peak M++) matches the mass of the peptide precursor ion after neutral loss of the O-Fuc-Glc disaccharide ($[M+2H-Glc]^{++}$). Note that peptide fragment ions appearing at this CE identify the sequence of the peptide with C-Man intact, positively localizing the glycan to the C-terminal Trp residue. Neutral loss of 120.04 Da from cross-ring cleavage is seen on the precursor and fragment peaks.




Figure S2c. CID at 1329.03 *m*/z, CE = 30 %. At this CE all parent precursor ion has been fragmented. The small peak at 1248.01 *m*/z remains, the mass of the precursor after neutral loss of Glc from the O-Fuc-Glc disaccharide ($[M+2H-Glc]^{++}$). The dominant peak is now 1174.98 *m*/z (yellow M++), the peptide precursor ion after neutral loss of the O-Fuc-Glc disaccharide ($[M+2H-Glc]^{++}$). Further peptide fragment ions confidently identify the sequence of the peptide with C-Man intact.




Figure S2d. CID at 1329.03 *m*/z, CE = 35 %. This is the CE typically used in shotgun proteomics methods. The C-mannosylated peptide precursor lacking the O-linked glycan remains the dominant peak, but peptide fragment ions are abundant enough to confidently sequence the peptide. Unlike the recombinant *Pf*CSP spectra in Figure 1 and supplemental Figure S1b, no peptide fragment ions with the O-linked glycan intact are visible at any CE. This is likely a signal-to-noise issue; the spectra in Figure 1 and Figure S1 were acquired by direct infusion of the peptide, allowing signal and ion fill time to be maximized, whereas these spectra were acquired on-the-fly by LC-MS/MS.





Figure S3. Glycoforms identified by automated sequence database search of data from LC-MS/MS analysis of recombinant *P. falciparum* **TRAP.** The variably C-mannosylated or oxidized Trp residues and the variably O-fucosylated Thr are underlined. Traces are offset for clarity. Peaks indicated with arrows were positively identified by PSMs. Both positional isoforms of the oxidized peptide were identified at several co-eluting retention times. See table S2.






Figure S4a,b. Representative MS² of the two 1248.01 m/z peaks eluting at **a**) 57.8 min and **b**) 58.9 min. The MS² from both species appear to identify the same species, i.e. the peptide modified with a gas-phase-labile moiety having a mass matching that of O-Fuc-Glc. The dominant species of the MS² spectra, 1093.95 m/z, matches the mass of the unmodified peptide. Additional PSMs are listed in Table S2.





Figure S4c,d. Representative MS² of the two 1093.5 *m*/z peaks eluting at **c)** 57.8 min and **d)** 58.9 min. The MS² from both species appear to identify the unmodified peptide. Both species co-elute with the 1248.01 m/z species identified in Fig. S4a and b, consistent with loss of the gas-phase-labile O-Fuc-Glc from in-source fragmentation. Additional PSMs are listed in Table S2.



S5. Misidentification of a glycoform in LC-MS/MS of recombinant P. falciparum TRAP

Figure S5a. Extracted Ion Chromatogram (XIC) of the precursor ion matching multiple isobaric glycoforms. The XIC of 1329.03 m/z (black line) is overlaid with squares showing points where MS² resulted in high-quality peptide spectrum matches (PSMs) identifying glycoforms of the recombinant *Pf*TRAP TSR peptide TASCGVWDEWSPCSVTCGK modified with combinations of C-linked mannose at tryptophan (green circle), O-linked fucose at the C-terminal threonine (red triangle) and β 1,3-linked glucose (blue circle) added to the fucose. See Table S2.




Figure S5b A single PSM (the yellow square in Figure S5a) was incorrectly identified as the glycoform of the peptide featuring double mannosylation and an O-Fuc, with the MS² annotated as shown here.




Figure S5c The same MS^2 from Figure S5b, re-annotated with the correct glycoform. While most of the fragment ions are the same as for the incorrect annotation (except y_{13}), the precursor fragment exhibiting neutral loss of O-Fuc-Glc (the yellow M++ peak) as well as cross-ring cleavage of C-man (yellow M++-120 peak) confirm that this is the correct annotation.




Figure S5d. The MS² for the same parent ion that immediately precedes the incorrect PSM, though sparse, identifies the correct glycoform.




Figure S5e. The MS² for the same parent ion immediately following the incorrect PSM identifies the correct glycoform, as do the remaining PSMs for the parent ion in the same chromatographic peak.

IQNSLSTEWSPCSVTCGNGIQVR




Figure S6. Representative XIC of glycosylated CSP from *P. falciparum* salivary gland **sporozoites.** The variably oxidized Trp and the variably O-fucosylated Thr are underlined. Traces are offset for clarity. Peaks indicated with arrows were positively identified by PSMs. The Hex of the O-Fuc-Hex disaccharide is indicated as a generic hexose because the identity of the glycan has not been confirmed.

P. falciparum salivary gland sporozoites Whole proteome




Figure S7. Representative XIC of glycosylated TRAP from *P. falciparum* salivary gland **sporozoites.** Traces are offset for clarity. Peaks marked with an orange asterisk (*) were not identified by PSMs because the precursor was not selected for MS², but their retention time and mass correspond with the indicted glycoform. The Hex of the O-Fuc-Hex disaccharide is indicated as a generic hexose because the identity of the glycan has not been confirmed.




Figure S8. Representative XIC of glycosylated CSP from *P. vivax* VK210 salivary gland sporozoites. The variably oxidized Trp and the variably O-fucosylated Thr are underlined. Traces are offset for clarity. Peaks indicated with arrows were positively identified by PSMs.




Figure S9. Representative XIC of glycosylated TRAP from *P. vivax* VK210 salivary gland **sporozoites.** The variably oxidized Trp residues and the variably O-fucosylated Thr are underlined. Traces are offset for clarity. Peaks indicated with arrows were positively identified by PSMs. Note that this sample contained a mixture of two field isolates, each of which carried a different version of the TRAP gene with either a Lys or Arg at the C-terminus of the glycopeptide.

ATVGTEWTPCSVTCGVGVR




Figure S10. Representative XIC of glycosylated CSP from *P. vivax* VK247 salivary gland sporozoites. The variably oxidized Trp and the variably O-fucosylated Thr are underlined. Traces are offset for clarity. Peaks indicated with arrows were positively identified by PSMs.




Figure S11. Representative XIC of glycosylated TRAP from *P. vivax* VK247 salivary gland sporozoites.




Figure S12. Representative XIC of glycosylated CSP from *P. yoelii* salivary gland sporozoites. Traces are offset for clarity. The reason for the doublet shape of the 1404.6 m/z and co-eluting 1331.6 m/z peaks is unknown, and may reflect spray instability or closely eluting isobaric species. Only the indicated glycopeptides were identified from MS² of these masses collected during the elution window of the peaks.




Figure S13. Representative XIC of glycosylated TRAP from *P. yoelii* salivary gland sporozoites.




Figure S14. Automated identification of TSR glycosylation in *P. yoelii* salivary gland sporozoites. A previously published proteomic analysis of salivary gland sporozoites of the rodent-infective *Plasmodium* species *P. yoelii* (Lindner and Swearingen *et al.* 2013 PMID:23325771) was reanalyzed with the mass offset approach described here, providing the first reported evidence of O-fucosylation and C-mannosylation of TSR domains in that species. Sample MS² spectra for the CSP peptide (top) and the TRAP peptide (bottom) are shown as automatically annotated by the Lorikeet spectrum viewer incorporated into the TPP. Both examples show a mass difference of -146.06 Da between the observed precursor *m/z* and that of the matched peptide, corresponding to neutral loss of O-Fuc. The C-mannosylated peptide precursor after neutral loss of O-Fuc is the dominant peak in both spectra (yellow peak annotated M++. In the CSP spectrum, this peak is isobaric with the b11-120 Da peak). Neutral loss of 120.04 Da from the M++ peak due to cross-ring cleavage of C-Man is also indicated.






Figure S15. Example false positive peptides showing neutral loss of O-linked glycans.



b+	b2+	#	Seq		y+	y2+
164.0706	82.5389	1	Y	37		
221.0921	111.0497	2	G	36	3005.1913	1503.0993
308.1241	154.5657	3	S	35	2948.1698	1474.5886
365.1456	183.0764	4	G	34	2861.1378	1431.0725
422.1670	211.5872	5	G	33	2804.1163	1402.5618
509.1991	255.1032	6	S	32	2747.0949	1374.0511
596.2311	298.6192	7	S	31	2660.0629	1330.5351
759.2944	380.1508	8	Y	30	2573.0308	1287.0191
816.3159	408.6616	9	G	29	2409.9675	1205.4874
903.3479	452.1776	10	S	28	2352.9460	1176.9767
960.3694	480.6883	11	G	27	2265.9140	1133.4606
1017.3908	509.1991	12	G	26	2208.8925	1104.9499
1074.4123	537.7098	13	G	25	2151.8711	1076.4392
1161.4443	581.2258	14	S	24	2094.8496	1047.9284
1324.5077	662.7575	15	Y	23	2007.8176	1004.4124
1381.5291	691.2682	16	G	22	1844.7543	922.8808
1468.5611	734.7842	17	S	21	1787.7328	894.3700
1525.5826	763.2949	18	G	20	1700.7008	850.8540
1582.6041	791.8057	19	G	19	1643.6793	822.3433
1639.6255	820.3164	20	G	18	1586.6578	793.8326
1696.6470	848.8271	21	G	17	1529.6364	765.3218
1753.6685	877.3379	22	G	16	1472.6149	736.8111
1810.6899	905.8486	23	G	15	1415.5934	708.3004
1947.7488	974.3781	24	н	14	1358.5720	679.7896
2004.7703	1002.8888	25	G	13	1221.5131	611.2602
2091.8023	1046.4048	26	s	12	1164.4916	582.7494
2254.8657	1127.9365	27	Y	11	1077.4596	539.2334
2311.8871	1156.4472	28	G	10	914.3962	457.7018
2398.9191	1199.9632	29	S	9	857.3748	429.1910
2455.9406	1228.4739	30	G	8	770.3428	385.6750
2542.9726	1271.9900	31	s	7	713.3213	357.1643
2630.0047	1315.5060	32	s	6	626.2893	313.6483
2717.0367	1359.0220	33	s	5	539.2572	270.1323
2774.0582	1387.5327	34	G	4	452.2252	226.6162
2831.0796	1416.0435	35	G	3	395.2037	198.1055
2994.1430	1497.5751	36	Y	2	338.1823	169.5948
		37	R	1	175.1190	88.0631



S 38 73.0340 2 3255.2867 1628,1470 154.5657 Y 37 3168.2546 1584.6310 3 183.0764 G 36 3005.1913 4 s 226.5924 5 35 2948.1698 255.1032 G 2861.1378 34 6 G 283.6139 7 33 2804.1163 327.1299 8 s 32 2747.0949 1374.0511 370.6459 9 S 2660.0629 31 452.1776 10 Y 2573.0308 30 480,6883 11 G 29 2409.9675 205.487 524.2043 12 s 28 2352.9460 552.7151 13 G 27 2265.9140 581.2258 14 G 26 2208.8925 1104.9499 G 609.7365 15 25 2151.8711 653.2525 S 16 24 2094.8496 734.7842 17 Y 23 2007.8176 763.2949 G 18 22 1844.7543 22.880 19 s 806.8110 21 1787.7328 94.3700 20 G 835.3217 20 1700.7008 850.8540 863.8324 21 G 1643.6793 19 G 892.3432 22 18 1586.6578 793.8326 920.8539 23 G 1529.6364 17 949.3646 G 1472.6149 24 736.8111 16 977.8753 25 G 15 1415.5934 708.3004 1046.4048 26 н 1358.5720 679.7896 1074.9155 27 G 13 1221.5131 611.2602 1118.4315 28 s 12 1164.4916 582,7494 1199.9632 29 Y 11 1077.4596 G 1228,4739 10 30 914.3962 457.7018 1271.9900 31 s 9 857.3748 429,1910 G 1300.5007 32 8 770.3428 385.6750 1344.0167 S 713.3213 357.1643 33 1387.5327 34 s 6 626.2893 313.6483 1431.0487 35 S 5 539.2572 270.1323 1459.5595 36 G 4 452.2252 226.6162 G 1488.0702 395.2037 198.1055 Y 1569.6019 38 338.1823 169.5948 39 R 175.1190 88.0631


b2+


Seq

G 39 y+

y2+

Figure S15c. The more likely correct annotation of the peptide from Figure S15b, matched to the fully tryptic peptide with no neutral loss.





b2+ # Seg # y+ y2+ 29.5180 1 G 39 S 3255.2867 1628,1470 73.0340 2 38 154,5657 Y 3168.2546 1584.6310 37 183.0764 G 3005.1913 36 226.5924 S 2948.1698 35 G 255.1032 2861.1378 283.6139 G 33 2804.1163 327,1299 S 2747.0949 s 370.6459 9 2660.0629 452,1776 10 Y 2573.0308 30 11 G 2409.9675 480.6883 29 1205.4874 12 S 524.2043 28 2352.9460 1176.9767 13 G 552.7151 2265.9140 27 581.2258 14 G 2208.8925 1104.9499 26 609.7365 15 G 25 2151.8711 653.2525 S 2094.8496 16 2. Υ 734.7842 17 2007.8176 27 763.2949 18 G 1844.7543 s 806.8110 19 1787.7328 G 1700.7008 835.3217 20 20 863.8324 21 G 1643.6793 822.3433 19 892.3432 22 G 1586.6578 793.8326 18 920.8539 23 G 1529.6364 765.3218 24 G 1472.6149 736.8111 949.3646 16 977.8753 25 G 1415.5934 708.3004 15 1046.4048 26 н 14 1358.5720 679.7896 1074,9155 G 1221.5131 611.2602 27 13 s 1118,4315 12 1164.4916 582.7494 28 Y 1199.9632 29 11 1077.4596 539.2334 G 1228.4739 10 914.3962 457.7018 30 S 9 857.3748 429.1910 1271.9900 1300.5007 32 G 770.3428 385.6750 8 1344.0167 33 S 713.3213 357.1643 s 1387.5327 34 626.2893 313.6483 1431.0487 35 S 539.2572 270.1323 36 G 452.2252 1459.5595 226.6162 37 G 1488.0702 395.2037 198,1055 1569.6019 38 Y 338.1823 169.5948 2 39 R 175.1190 88.0631

Figure S15e. The more likely correct annotation of the peptide from Figure S15d, matched to the fully tryptic peptide with no neutral loss